dMMR Recurrent or Advanced Solid Tumors | JEMPERLI (dostarlimab-gxly)
Efficacy | Tivdak® (tisotumab vedotin-tftv)
Forest plot of the comparison of overall response rate (ORR).
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Overall response rate | Download Table
Visualization of efficacy endpoints in oncology clinical trials
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Durable Response Rate
Efficacy | BALVERSA® (erdafitinib) HCP
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma | Semantic Scholar
Efficacy - Overall Response Rate | Aliqopa US HCP
ORR (Objective Response Rate) and related statistics – Part 1
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Objective response rate assessment in oncology: Current situation and future expectations
Best Overall Response Rate (full analysis population) | Download Table
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Cell therapy doubles survival, response rates in advanced melanoma
ODOMZO® (sonidegib) | Efficacy Data
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
Efficacy endpoints in Oncology
